ARQT
Arcutis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
FDA Approved
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARQT
Arcutis Biotherapeutics, Inc.
A late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology
3027 Townsgate Road Suite 300, Westlake Village, California 91361
--
Arcutis Biotherapeutics, Inc., formerly known as Arcutis, Inc., was established in June 2016 under the laws of the State of Delaware and later changed its name to Arcutis Biotherapeutics, Inc. The company is a late-stage biopharmaceutical company dedicated to the development and commercialization of treatments for skin diseases with unmet medical needs. The company's current product portfolio includes topical treatments with the potential to address immune-mediated skin diseases and diseases or immune skin diseases. The company's strategy is to identify and develop therapies against proven biological targets in dermatology to provide differentiated clinical features that address the major shortcomings of existing therapies in terms of target indications.
Earnings Call
Q1/2025
Estimate EPS-0.21
Actual EPS-0.2
Estimate Revenue62.48M
Actual Revenue65.80M
Arcutis Biotherapeutics Q1 2025: Navigating Contradictions in ZORYVE Foam Strategy and Market Dynamics
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.16
Actual EPS-0.13
Estimate Revenue73.67M
Actual Revenue81.50M
Kowa's 2025 Q2 Earnings Call: Unpacking Contradictions in Gross to Net Dynamics, Seasonality, and Medicare Coverage
Aug 11,2025 07:49
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ARQT has released its 2025 Q3 earnings. EPS was reported at 0.06, versus the expected -0.1, beating expectations. The chart below visualizes how ARQT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ARQT has released its 2025 Q3 earnings report, with revenue of 99.22M, reflecting a YoY change of 121.69%, and net profit of 7.41M, showing a YoY change of 117.84%. The Sankey diagram below clearly presents ARQT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
